
Our take on Avidity's FORTITUDE phase 1/2 trial data
Update: 2025-06-11
Share
Description
"I'll have what she's having." We'll take you through and discuss the recent release of Avidity Biosciences topline results from the phase 1/2 FORTITUDE trial and the preliminary data from the biomarker cohort extension.
Comments
In Channel